BioBridge Global adds two industry leaders to Regenerative Medicine Advisory Board
06 mai 2019 09h00 HE | BioBridge Global
San Antonio, Texas, May 06, 2019 (GLOBE NEWSWIRE) -- BioBridge Global has added two new members to its Regenerative Medicine Advisory Board, a group composed of industry leaders with a wide range of...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
01 févr. 2019 07h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
18 janv. 2019 07h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
17 janv. 2019 07h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
07 janv. 2019 07h06 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D.,...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
21 déc. 2018 10h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company,  today announced that the Company has been selected...
Avrobio_logo_no_strapline.jpg
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR-RD-01 for the Treatment of Fabry Disease
19 déc. 2018 07h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
18 déc. 2018 07h05 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires
18 déc. 2018 07h00 HE | AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior...
Avrobio_logo_no_strapline.jpg
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
13 nov. 2018 08h00 HE | AVROBIO, Inc.
During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE...